'김갑성' 기자의 전체기사
-
BostonGene Receives Frost & Sullivan's 2025 North American E…
BostonGene's comprehensive AI-powered platform integrates multiomics data to accelerate discovery, reduce development risk and advance precision oncology across all stages the R&D continuum SAN ANTONIO, July 22, 2025 -- Frost & Sullivan has named BostonGene the recipient of the 2025 North American Enabling Technology Leadership Award in recognition of the company's pioneering role in advancing precision oncology. BostonGene's clinically validated, AI-powered platform uses a multimodal approach to decode disease and uncover predictive biological signatures. BostonGene c
- 김갑성 기자
- 2025-07-22 22:00
-
LG AI Research Showcases 'EXAONE Ecosystem' at LG AI Talk…
[ 메디채널 김갑성 기자 ] Pioneering AI Transformation from Bio to Business Intelligence SEOUL, South Korea, July 22, 2025 -- LG AI Research hosted its "LG AI Talk Concert 2025" today at the LG Sciencepark Convergence Hall in Magok, Seoul, showcasing the evolution of its EXAONE ecosystem. The event highlighted the culmination of five years of AI development, featuring advanced AI models and services designed for real-world industrial applications. Woohyung Lim, Co-President of LG AI Research, outlined future plans, stating, "LG AI Research will secure global competitivene
- 김갑성 기자
- 2025-07-22 22:00
-
Kolmar Korea Launches Full Operation of 2nd US Factory, Es…
New 17,805㎡ facility completed in Pennsylvania with an annual production capacity of 300 million units Full ODM production capabilities in the US — from color cosmetics to skincare and suncare — mitigating tariff and supply chain risks 'MADE BY KOLMAR' world-class manufacturing technology localized to the US market OLYPHANT, Pa. and SEOUL, South Korea, July 22, 2025 -- Kolmar Korea has officially completed construction and begun full-scale operations of its second manufacturing facility in the United States, the world's largest cosmetics market. Located in Scott Townsh
- 김갑성 기자
- 2025-07-22 20:30
-
A novel oral treatment for Alzheimer's: Actinogen's pivotal tria…
All 20 US trial sites are now open in the XanaMIA phase 2b/3 trial that is studying oral Xanamem® vs. placebo for 36 weeks, followed by an open label extension of active Xanamem for up to 24 months SYDNEY, July 22, 2025 -- Actinogen Medical Limited (ASX: ACW) is encouraging individuals and their loved ones affected by Alzheimer's disease to take part in a groundbreaking clinical trial that could transform the way we treat this devastating condition. The trial is enrolling people diagnosed with mild to moderate Alzheimer's disease, offering them a chance
- 김갑성 기자
- 2025-07-22 20:00
-
Telix Reports $204M Revenue, Up 63% YOY
MELBOURNE, Australia and INDIANAPOLIS, July 22, 2025 -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today provides an update on its commercial and operational performance for the quarter ended 30 June 2025 (Q2 2025). All figures are in USD unless stated otherwise. Q2 2025 Highlights Q2 2025 unaudited group revenue of approximately $204 million, up 63% year-over-year. FY 2025 revenue guidance of $770 million to $800 million is reaffirmed. Gozellix® launched in the U.S. and commercial dose deliveries commenced. Gozel
- 김갑성 기자
- 2025-07-22 16:02
-
METiS Technologies Showcases AI-Powered Nanodelivery…
HANGZHOU, BEIJING, China and CAMBRIDGE, Mass., July 22, 2025 -- METiS Technologies, a global leader in AI-driven nanodelivery innovation, today announced the presentation of its latest research findings at the poster session of the 2025 Controlled Release Society (CRS) Annual Meeting. The company demonstrated that its proprietary AiLNP platform enables the rapid design of tissue-targeted lipid nanoparticles (LNPs), which exhibit high delivery efficiency, strong tissue specificity, and excellent translatability in non-human primates (NHPs). Founded in 1978, the Controlled Releas
- 김갑성 기자
- 2025-07-22 15:52
-
DualityBio's Next-Generation HER3 ADC DB-1310 Granted FDA Fast T…
SHANGHAI, July 22, 2025 -- DualityBio (HKEX Stock Code: 9606.HK) announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation (FTD) to its next-generation HER3-targeting antibody-drug conjugate (ADC) DB-1310. This designation is for the treatment of adult patients with advanced, unresectable or metastatic nonsquamous non-small cell lung cancer (nsqNSCLC) with an EGFR exon 19 deletion or L858R mutation with disease progression on or after treatment with a third-generation EGFR tyrosine kinase inhibitor (TKI) and platinum-based chemotherapy. &
- 김갑성 기자
- 2025-07-22 10:25
-
Precision Era to Redefine Treatment, Drive $450B Economic Inv…
SINGAPORE, July 22, 2025 -- The Precision Era of medicine is arriving in Asia Pacific, driven by the arrival of a critical mass of innovative therapies that will redefine treatment, attract investment and improve lives, a new expert-driven report finds. Released today, 'On the Cusp of a Cure' White Paper examines Asia Pacific's readiness for the Precision Era – the current, transformative period where generically prescribed and regularly administered treatments are increasingly giving way to potentially curative therapies tailored to individuals and their disease. Treatments called pre
- 김갑성 기자
- 2025-07-22 10:07
-
OMRON Healthcare Singapore partners with bolttech and QBE…
The comprehensive subscription programme offers OMRON customers in Singapore access to personalised health protection and insights SINGAPORE, July 22, 2025 -- Global insurtech bolttech and OMRON Healthcare Singapore, a global leader in innovative medical equipment for health monitoring and therapy, today announced the launch of their Premium Care subscription plan in Singapore. This three-in-one premium subscription programme offers registered OMRON connect members personalised health insights, protection and exclusive services tailored to OMRON device owners. Underwritten by
- 김갑성 기자
- 2025-07-22 09:30
-
CPHI & PMEC 선전 2025: 아시아와 그레이터 베이 지역에 새로운 기회 창출
[ 메디채널 김갑성 기자 ] 상하이 2025년 7월 22일 -- CPHI & PMEC 차이나 2025(CPHI & PMEC China 2025) 가 6월에 막을 내리며 총 109056명의 역대 최다 참관객을 기록, 중국 제약 산업의 강력한 수요를 다시 한번 입증했다. 이러한 성공을 바탕으로 CPHI & PMEC 선전 2025(CPHI & PMEC Shenzhen 2025)가 2025년 9월 1일부터 3일까지 선전 컨벤션 및 전시 센터(Shenzhen Convention & Exhibition Center, SZCEC)에서 개최된다. 이번 행사는 중국 남부의 주요 제약 시장에 대한 접근 수요 증가에 대응하기 위해 마련됐다. 광둥-홍콩-마카오 그레이터 베이 지역(Guangdong-Hong Kong-Macau Greater Bay Area)의 핵심 관문인 선전은 제약 혁신의 중심지로 부상하고 있다. 이 지역의 헬스 산업 GDP는 2028년까지 2조 위안을 넘어서고 2030년에는 2조 5천억~3조 위안에 이를 것으로 전망되며, 이로 인해 성장과 협업 기회가 전례 없이 확대될 것으로 예상
- 김갑성 기자
- 2025-07-22 08:26
- 1포리프 굿마팻 (누바디 굿바이 마이팻) 다이어트 건강기능식품 출시
- 22021년 식품분석전문가 1급/2급 검정자격시험 안내
- 3투썸플레이스, 초콜릿 애프리콧 무스 출시
- 4만성질환자들의 유료독감백신접종에 정책적인 배려가 필요하다
- 5아임웹, CRM 기능 출시… 고객 행동 데이터 기반 마케팅 지원
- 6하만카돈, AURA STUDIO 4 블루투스 스피커 출시
- 7대구오페라하우스 - 20주년 기념 골든 보이스 시리즈Ⅲ, 테너 콘서트
- 82021년 대학생기자단 모집
- 9대한약물영양의학회 2020년 추계학술대회
- 10대한영양제처방학회 춘계학술대회 성황리에 마쳐
2025-10-20_MON
- CARsgen Presents Preliminary Results on Satri-cel for Adjuvant Therapy of Pancreatic Cancer at ESMO Congress 2025 08:15
- Ascletis Completes Enrollment in U.S. Phase IIa Study for Its Once-Monthly Subcutaneous Depot Treatment Formulation of Small Molecule GLP-1R Agonist ASC30 for Obesity 08:10
- ESMO 2025: CStone Discloses Phase I Data for CS2009 (PD-1/VEGF/CTLA-4 Trispecific Antibody) 08:10
- Leading Competition Economist Dr. Luke Wainscoat Joins The Brattle Group 07:25
- Clover Appoints Nicholas Jackson, Ph.D., as President of Global R&D and Alliances 07:00
- Webull Reduces Minimum ASX Trading Fee To $1 06:00
- Yaber Expands Its Global Footprint -- Now Available at JB Hi-Fi Across Australia 05:00
발행인 : 최희정 | 편집인 : 김갑성 |
등록번호: 서울특별시 아53302 | 등록일 2020-09-25 | 전화번호 02-565-7119 |
주소 : 서울특별시 강남구 영동대로 602, 6층 E115 (삼성동)
Copyright @메디채널 Corp. All rights reserved.
UPDATE: 2025년 10월 20일 09시 40분